OVX836 is a first-in-class influenza A vaccine candidate that targets the nucleoprotein ... Osivax’ oligoDOM technology enables the design and production of a recombinant version of the NP which ...

Protection from shots like the flu vaccine typically takes a couple of weeks to kick in, so getting one now may offer ...

The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by ... using traditional cell culture or recombinant techniques. The 25,000-subject ...

Recombinant protein vaccines ... The Cleveland Clinic researchers are hopeful that human trials of their universal flu ...

Hope is on the horizon for needle-phobic patients as Griffith University researchers have created a new influenza vaccine ...

On 1, Novavax, Inc. (NASDAQ:NVAX) and the U.K. Health Security Agency, representing the U.K. Secretary of State for Health ...

Gaithersburg: Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M adjuvant, has announced that ...

The first research programs attempting to develop an inactivated influenza vaccine, outside of the USSR, were conducted in England and in the USA at about the same time. However, it was at the ...

These individuals received either quadrivalent recombinant influenza vaccine [Flublock Quadrivalent; RIV4]) (30.7%; n=14,981) or a comparator standard-dose quadrivalent inactivated influenza ...

In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...

Protection from shots like the flu vaccine typically takes a couple of ... will be available this season are egg-based and cell- or recombinant-based, according to the CDC.